Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody- mediated apoptosis

Journal of Hepatology

Volumn 31, Issue 2, 1999, Pages 315-322

  Takahashi, Masahiko ^a,b   Saito, Hidetsugu ^a   Okuyama, Torayuki ^a,b   Miyashita, Toshiyuki ^b   Kosuga, Motomichi ^a,b   Sumisa, Futoshi ^b   Yamada, Masao ^b   Ebinuma, Hirotoshi ^a   Ishii, Hiromasa ^a  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Antisense oligonucleotide; Gene transfer; Human hepatoma cell line

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA GALACTOSIDASE; FAS ANTIGEN; PROTEIN BCL 2;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIGAND BINDING; ONCOGENE; PRIORITY JOURNAL;

EID: 0032775972     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80230-X     Document Type: Article

References (43)

1. Korsmeyer SJ. Regulators of cell death. Trends Genet. 11:1995;101-105.
2. Chiu VK, Walsh CM, Liu CC, Reed JC, Clark WR. Bcl-2 blocks degradation but not Fas-based cytotoxicity. J Immunol. 154:1995;2023-2032.
3. Itoh N, Tsujimoto Y, Nagata S. Effect of Bcl-2 on Fas antigenmediated cell death. J Immunol. 151:1993;621-627.
4. Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T. Bcl-2 protects from lethal hepatic apoptosis induced by the anti-Fas antibody in mice. Nat Med. 2:1996;80-86.
5. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 95:1995;2633-2643.
6. Memon SA, Moreno MB, Petrak D, Zacharchuk CM. Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma. J Immunol. 155:1995;4644-4652.
7. Moreno MB, Memon SA, Zacharchuk CM. Apoptosis signaling pathways in normal T cells - differential activity of Bcl-2 and IL-1b-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity. J Immunol. 157:1996;3845-3849.
8. Nagata S, Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
9. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the NGF/TNF receptor superfamily, in normal and neoplastic cells. Lab Invest. 69:1993;415-429.
10. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 182:1995;1223-1230.
11. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
12. Suda T, Nagata S. Purification and characterization of the Fasligand that induces apoptosis. J Exp Med. 179:1994;873-879.
13. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for the human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233-243.
14. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301-304.
15. Krammer PH, Behrmann I, Daniel P, Dhein D, Debatin KM. Regulation of apoptosis in the immune system. Curr Opin Immunol. 6:1994;279-289.
16. Patel TC, Gores GJ. Apoptosis and hepatobiliary diseases. Hepatology. 21:1995;1725-1741.
17. Charlotte F, L'Herminé A, Martin N, Geleyn Y, Nollet M, Gaulard P, et al. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol. 144:1994;460-465.
18. Zhao M, Zhang NX, Economou M, Blaha I. Immunohistochemical detection of bcl-2 protein in liver lesions: bcl-2 protein is expressed in hepatocellular carcinomas but not in liver cell dysplasia. Histopathology. 25:1994;237-245.
19. Zeppa P, Benincasa G, Fulciniti F, Cochand-Priollet B, Troncone G, Vetrani A, et al. Apoptosis and cytologic differentiation in hepatocellular carcinoma on fine needle aspiration samples. Acta Cytol. 40:1996;861-866.
20. Terada T, Nakamura Y. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewisy and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Pathol Int. 46:1996;764-770.
21. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 282:1979;615-616.
22. Saito H, Morizane T, Watanabe T, Kagawa T, Iwabuchi N, Kumagai N, et al. Establishment of a human cell line (HCC-T) from a patient with hepatoma bearing no evidence of hepatitis B or A virus infection. Cancer. 64:1989;1054-1060.
23. Saito H, Tada S, Ebinuma H, Tsunematsu S, Kagawa T, Kumagai N, et al. Changes of antigen expression on human hepatoma cell lines caused by sodium butyrate, a differentiation inducer. J Gastroenterol. 29:1994;733-739.
24. Le MT, Okuyama T, Cai SR, Kennedy SC, Bowling WM, Flye MW, et al. Therapeutic levels of functional human Factor X in rats after retroviral-mediated hepatic gene therapy. Blood. 89:1997;1254-1259.
25. Okuyama T, Huber RM, Bowling W, Pearline R, Kennedy SC, Flye MW, et al. Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-αl-antitrypsin promoter dramatically increases expression of human αl-antitrypsin in vivo. Hum Gene Ther. 7:1996;637-645.
26. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA. 83:1986;5214-5218.
27. Kovacs DM, Kaplan BB. Discordant estimate of heterologous promoter activity as determined by reporter gene mRNA levels and enzyme activity. Biochem Biophys Res Commun. 189:1992;912-918.
28. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 84:1987;7413-7417.
29. Sutherland LC, St. Arnaud R, McBurney MW. An upstream activator sequence regulates the murine Pgk-1 promoter and binds multiple nuclear proteins. Gene Expr. 4:1995;265-279.
30. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. Hightiter packaging cells producing recombinant retroviruses resistant to human serum. J Virol. 69:1995;7430-7436.
31. Okuyama T, Li X-K, Funeshima N, Fujino M, Sasaki K, Kita Y, et al. Fas-mediated apoptosis is involved in the elimination of gene-transduced hepatocytes with E1/E3-deleted adenoviral vectors. J Gastroenterol Hepatol. 1999;. in press.
32. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, et al. Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res. 51:1991;6529-6538.
33. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81:1993;151-157.
34. Reed JC, Stein C, Subasinghe C, Halder S, Croce C, Yum S, et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 50:1990;6565-6570.
35. Lootiens FG, Regenfuss P, Zechel A, Dumortier L, Clegg RM. Binding d(CCGGAATTCCGG): multiple stoichiometries and determination of tight binding with a wide spectrum of site affinities. Biochemistry. 29:1990;9029-9039.
36. Saito H, Ebinuma H, Takahashi M, Kaneko F, Wakabayashi K, Nakamura M, et al. Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression. Hepatology. 27:1998;1233-1240.
37. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 169:1989;1747-1756.
38. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 19:1994;1354-1359.
39. Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, et al. The role of fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun. 204:1994;468-474.
40. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
41. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 89:1997;1067-1076.
42. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell. 85:1996;803-815.
43. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al. Flice, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-in-ducing signaling complex. Cell. 85:1996;817-827.